the US$750 million private placement in the US; and
the equivalent of approximately AU$800 million, at current exchange rates, in new lines of credit with its banks.

More.

17/08/2011
Full Year Results Announcement for 2010/11
CSL Limited today reported a net profit after tax of $941 million for the twelve months ended 30 June 2011, down $112 million or 11% when compared to the prior comparable period. More.

17/08/2011
CSL Announces Changes to the Board
CSL Limited (ASX:CSL) today announced that Chairman, Miss Elizabeth Alexander, AM, and Director, Mr David Simpson, have indicated their intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 19 October 2011. More.

22/06/2011
CSL Biotherapies Statement on FDA Warning Letter for GMP issues at Australian Influenza Vaccine Facility
Today the US Food and Drug Administration (FDA) published a Warning Letter issued by its Office of Compliance and Biologics Quality to CSL Biotherapies, a division of CSL Limited. The FDA regulates the manufacture, marketing and distribution of CSL Biotherapies’ influenza vaccine, Afluria^®, in the US market. More.

20/05/2011
Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
CSL Limited (ASX:CSL) subsidiary, CSL Behring, today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B. More.

29/03/2011
Changes to CSL Senior Executive Group
CSL Limited (ASX:CSL) Australia’s leading biopharmaceutical company, today announced a change to its senior executive group. More.

16/02/2011
Half-year results announcement for 2010/11
CSL Limited today announced its first half result for period ended 31 December 2010. More.

16/02/2011
CSL Appoints New Director
CSL Limited (ASX:CSL) today announced that Ms Christine O’Reilly has been appointed a Director of the Company effective from 16 February 2011. More.

18/08/2010
Full-year results for 2009/10
CSL Limited today announced a profit after tax of $1,053 million for the twelve months ended 30 June 2010. More.

17/02/2010
Half-year results announcement for 2009/10
CSL Limited today announced its first half result for period ended 31 December 2009. More.

>> Prior ASX Releases

Investors Contact

Mark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
Email: mark.dehring@csl.com.au
45 Poplar Rd
Parkville
Victoria 3052
Australia

Privacy | Terms of Use | Employees | Webmaster